Dyne Therapeutics (DYN) Insider Jason Rhodes Sells $509K of Stock

Insider Buying and Selling at Dyne Therapeutics, Inc.

Jason Rhodes executed a planned sale of 24,100 shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) on June 25, 2026. The transaction took place at a price of $21.10 per share, resulting in a total value of $508,510. This disposal was handled according to a pre-arranged trading schedule, adding to a series of recent stock dispositions by company insiders during the month of June.

Additional Insider Disposals in June

This transaction follows multiple other insider sales recorded by Dyne Therapeutics over a busy two-week stretch. On June 26, 2026, Jason Rhodes parted with another block of 309,268 shares valued at approximately $6.58 million. Earlier in the month, on June 23, 2026, Rhodes also disposed of 147,760 shares for about $3.12 million. Chief Financial Officer Erick Lucera also trimmed his holdings on June 25, 2026, selling 2,362 shares for $48,114. Additional sales came from Dirk Kersten, who executed transactions including a 190,676-share sale on June 22, 2026, worth $3.92 million, and a 46,901-share sale on June 18, 2026, valued at $941,303. Such planned sales are common among executives and major stakeholders for personal portfolio management.

Stock Price Levels and Valuation

Dyne Therapeutics shares changed hands recently around the $20.94 mark. The equity sits comfortably above its 200-day moving average of $19.78, while moving below its 50-day moving average of $23.85. Over the past year, the stock has traded between a low of $11.92 and a peak of $27.30. The company carries a market valuation of roughly $3.2 billion.

Analysts Set New Price Targets

Wall Street research firms continue to monitor the biotechnology company closely, maintaining a strong buy consensus overall alongside a mean price target of $37.20 based on 15 analyst opinions. Recent updates from financial institutions show active coverage adjustments. On September 30, 2026, Chardan Capital kept a buy rating and a $38.00 target, while HC Wainwright & Co. maintained a buy rating while shifting its target to $32.00 from $50.00. Piper Sandler kept an overweight rating with a $47.00 target on September 29, 2026. Morgan Stanley maintained an overweight rating with a $36.00 target on September 9, 2026, while JP Morgan lowered its view to an underweight rating with a $10.00 target on the same day. RBC Capital kept an outperform rating with a $30.00 target, and Baird maintained an outperform rating with a $26.00 target.

Focus on Muscle Disease Therapeutics

Dyne Therapeutics is a clinical-stage organization centered on creating treatments for severe muscle conditions. The enterprise applies its FORCE delivery framework to build a pipeline targeting disorders such as myotonic dystrophy type 1, duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease. These efforts aim to address critical unmet needs in neuromuscular and metabolic health.

Outlook and Upcoming Financial Reports

Market participants will look forward to the company's next financial results release, which is scheduled for November 5, 2026. Further regulatory filings will provide additional visibility into institutional ownership shifts and insider sentiment as clinical developments progress.